Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Folker Westphal

Showing results (31-40 of 61) with videos related to

Pageof 7
Sort By:
British Journal of Clinical Pharmacology|June 16, 2025
Metabolic fate of drugs of abuse and new psychoactive substances: A pilot study on a novel workflow using a zebrafish embryo model combined with human microdosingSimon K Wellenberg, Tanja M Gampfer, Lea Wagmann, et al.
Drug Testing and Analysis|September 4, 2020
Synthetic cannabinoid receptor agonists: Analytical profiles and development of QMPSB, QMMSB, QMPCB, 2F-QMPSB, QMiPSB, and SGT-233Simon D Brandt, Pierce V Kavanagh, Folker Westphal, et al.
Drug Testing and Analysis|January 10, 2017
Analysis of six 'neuro-enhancing' phenidate analogsHelge Klare, Jörg M Neudörfl, Simon D Brandt, et al.
Drug Testing and Analysis|October 13, 2015
Return of the lysergamides. Part I: Analytical and behavioural characterization of 1-propionyl-d-lysergic acid diethylamide (1P-LSD)Simon D Brandt, Pierce V Kavanagh, Folker Westphal, et al.
Frontiers in Chemistry|August 9, 2020
How to Study the Metabolism of New Psychoactive Substances for the Purpose of Toxicological Screenings-A Follow-Up Study Comparing Pooled Human Liver S9, HepaRG Cells, and Zebrafish LarvaeLea Wagmann, Fabian Frankenfeld, Yu Mi Park, et al.
Data in Brief|January 6, 2022
Dataset allowing for the identification of three new synthetic cannabimimetics featuring a norbornyl methyl side chain by spectrometric and spectroscopic techniquesBenedikt Pulver, Jan Riedel, Torsten Schönberger, et al.
Drug Testing and Analysis|September 3, 2019
Detection and phase I metabolism of the 7-azaindole-derived synthetic cannabinoid 5F-AB-P7AICA including a preliminary pharmacokinetic evaluationArianna Giorgetti, Lukas Mogler, Belal Haschimi, et al.
Drug Testing and Analysis|March 31, 2021
New synthetic cannabinoids carrying a cyclobutyl methyl side chain: Human Phase I metabolism and data on human cannabinoid receptor 1 binding and activation of Cumyl-CBMICA and Cumyl-CBMINACABelal Haschimi, Katharina Elisabeth Grafinger, Benedikt Pulver, et al.
Drug Testing and Analysis|June 15, 2023
Analytical and behavioral characterization of N-ethyl-N-isopropyllysergamide (EIPLA), an isomer of N<sup>6</sup> -ethylnorlysergic acid N,N-diethylamide (ETH-LAD)Simon D Brandt, Pierce V Kavanagh, Folker Westphal, et al.
Drug Testing and Analysis|May 18, 2017
Syntheses, analytical and pharmacological characterizations of the 'legal high' 4-[1-(3-methoxyphenyl)cyclohexyl]morpholine (3-MeO-PCMo) and analoguesTristan Colestock, Jason Wallach, Matt Mansi, et al.
Pageof 7

Showing results (31-40 of 61) with videos related to

Sort By:
Pageof 7
British Journal of Clinical Pharmacology|June 16, 2025
Metabolic fate of drugs of abuse and new psychoactive substances: A pilot study on a novel workflow using a zebrafish embryo model combined with human microdosingSimon K Wellenberg, Tanja M Gampfer, Lea Wagmann, et al.
Drug Testing and Analysis|September 4, 2020
Synthetic cannabinoid receptor agonists: Analytical profiles and development of QMPSB, QMMSB, QMPCB, 2F-QMPSB, QMiPSB, and SGT-233Simon D Brandt, Pierce V Kavanagh, Folker Westphal, et al.
Drug Testing and Analysis|January 10, 2017
Analysis of six 'neuro-enhancing' phenidate analogsHelge Klare, Jörg M Neudörfl, Simon D Brandt, et al.
Drug Testing and Analysis|October 13, 2015
Return of the lysergamides. Part I: Analytical and behavioural characterization of 1-propionyl-d-lysergic acid diethylamide (1P-LSD)Simon D Brandt, Pierce V Kavanagh, Folker Westphal, et al.
Frontiers in Chemistry|August 9, 2020
How to Study the Metabolism of New Psychoactive Substances for the Purpose of Toxicological Screenings-A Follow-Up Study Comparing Pooled Human Liver S9, HepaRG Cells, and Zebrafish LarvaeLea Wagmann, Fabian Frankenfeld, Yu Mi Park, et al.
Data in Brief|January 6, 2022
Dataset allowing for the identification of three new synthetic cannabimimetics featuring a norbornyl methyl side chain by spectrometric and spectroscopic techniquesBenedikt Pulver, Jan Riedel, Torsten Schönberger, et al.
Drug Testing and Analysis|September 3, 2019
Detection and phase I metabolism of the 7-azaindole-derived synthetic cannabinoid 5F-AB-P7AICA including a preliminary pharmacokinetic evaluationArianna Giorgetti, Lukas Mogler, Belal Haschimi, et al.
Drug Testing and Analysis|March 31, 2021
New synthetic cannabinoids carrying a cyclobutyl methyl side chain: Human Phase I metabolism and data on human cannabinoid receptor 1 binding and activation of Cumyl-CBMICA and Cumyl-CBMINACABelal Haschimi, Katharina Elisabeth Grafinger, Benedikt Pulver, et al.
Drug Testing and Analysis|June 15, 2023
Analytical and behavioral characterization of N-ethyl-N-isopropyllysergamide (EIPLA), an isomer of N<sup>6</sup> -ethylnorlysergic acid N,N-diethylamide (ETH-LAD)Simon D Brandt, Pierce V Kavanagh, Folker Westphal, et al.
Drug Testing and Analysis|May 18, 2017
Syntheses, analytical and pharmacological characterizations of the 'legal high' 4-[1-(3-methoxyphenyl)cyclohexyl]morpholine (3-MeO-PCMo) and analoguesTristan Colestock, Jason Wallach, Matt Mansi, et al.
Pageof 7